The tests include blood based gene expression assays for the early diagnosis of breast and lung cancer, as well as a blood based test for determining survival and therapy response in melanoma.

The tests are protected by a broad portfolio of over 30 US and international patent filings.

DxTerity has begun the process of migrating these tests to its revolutionary NEAT (Non-Enzymatic Amplification Technology) platform.

DxTerity Diagnostics CEO Bob Terbrueggen said the NEAT platform is perfect for blood based genomic testing since it enables the simultaneous direct from sample measurement of up to 40 gene targets.

"The Breast, Lung and Melanoma tests represent significant steps forward in the treatment of life threatening diseases, and DxTerity’s technology enables the low-cost delivery of these tests," Terbrueggen said.